D'Arena G, Musto P, Cascavilla N, Dell'Olio M, Di Renzo N, Perla G, Savino L, Carotenuto M
Division of Hematology, IRCCS Casa Sollievo della Sofferenza Hospital, 71013 San Giovanni Rotondo, Italy.
Leuk Lymphoma. 2001 Jun;42(1-2):109-14. doi: 10.3109/10428190109097682.
CD38 identifies a surface molecule with multi-functional activity. Its prognostic importance in B-cell chronic lymphocytic leukemia (B-CLL) is currently under investigation in view of the fact that two different groups have recently indicated that CD38 expression could be an independent prognostic marker in B-CLL. We analyzed the clinico-biological features of 61 immunologically typical (CD5+CD23+) B-CLL patients stratified according to the CD38 expression. Twenty-two (36%) patients expressed CD38 in more than 30% of CD19-positive cells and were considered as CD38-positive B-CLL. Atypical morphology (p 0.02), peripheral blood lymphocytosis (p 0.01) and diffuse histopathologic bone marrow pattern (p 0.003) were findings found to be closely associated with CD38 expression. On the other hand, A and B Binet stages (p 0.02) and interstitial bone marrow involvement (p 0.005) were more represented in the CD38-negative B-CLL group. Trisomy 12 was detected more frequently in the CD38-positive B-CLL group, while 13q14 deletions mainly occurred in CD38-negative group (p 0.005). Finally, median survival of CD38-positive B-CLL patients was 90 months, while it was not reached at 180 months in CD38-negative patients. Taken together, our data strongly suggest that the evaluation of CD38 expression may identify two groups patients with B-CLL greatly differing in their clinico-biological features.
CD38识别一种具有多功能活性的表面分子。鉴于最近有两个不同的研究小组指出CD38表达可能是B细胞慢性淋巴细胞白血病（B-CLL）的独立预后标志物，目前正在对其在B-CLL中的预后重要性进行研究。我们分析了61例根据CD38表达分层的免疫典型（CD5+CD23+）B-CLL患者的临床生物学特征。22例（36%）患者在超过30%的CD19阳性细胞中表达CD38，被视为CD38阳性B-CLL。发现非典型形态（p=0.02）、外周血淋巴细胞增多（p=0.01）和弥漫性组织病理学骨髓模式（p=0.003）与CD38表达密切相关。另一方面，A和B期Binet分期（p=0.02）和间质骨髓受累（p=0.005）在CD38阴性B-CLL组中更为常见。12号染色体三体在CD38阳性B-CLL组中更频繁地被检测到，而13q14缺失主要发生在CD38阴性组（p=0.005）。最后，CD38阳性B-CLL患者的中位生存期为90个月，而CD38阴性患者在180个月时未达到中位生存期。综上所述，我们的数据强烈表明，评估CD expressing CD38 expression may identify two groups patients with B-CLL greatly differing in their clinico-biological features.
